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ABSTRACT 
 
Clara cell secretory protein 16KDa (CC16) is the major secretory protein of the Clara 
cells. The gene encoding CC16 has been implicated as potential susceptibility gene 
for asthma. Published studies between genetic polymorphism of CC16 at position 38 
and asthma risk are controversial. Most of these studies are based on small sample 
size. To clarify the role of the A38G CC16 polymorphism on the risk of developing 
asthma, we carried out a meta-analysis of the research published between January 
1988 and August 2005. In the present study, 11 case-control studies with 2362 
subjects (1262 controls and 1100 patients) were eligible for meta-analysis. The fixed-
effects method was used when there was no significant heterogeneity between the 
results of the individual studies being pooled, whereas, the random-effects method 
was used when there was heterogeneity between the studies. The overall ORs of the 
asthma risk were not associated with the CC16 genotypes (For AG vs GG: OR=1.09, 
95% CI: 0.90-1.32; For AA vs GG: OR=1.05, 95% CI: 0.79-1.39; For AG+AA vs 
GG: OR=1.09, 95% CI: 0.91-1.30). It should be noted that similar results were 
obtained when we used the stratified data, adjusted for age and smoking status of the 
subjects. In conclusion, the CC16 A38G polymorphism was not associated with 
asthma risk in the present meta-analysis. 
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INTRODUCTION 
 
A genetic component to asthma and 
atopy has been suggested (Malerba and 
Pignatti, 2005). Genome-wide searches 
and candidate gene studies have 
identified many genes and regions that 
potentially influence asthma 
susceptibility (Daniels et al., 1996; 
Malerba and Pignatti, 2005). The human 
chromosome 11q12-13 is one of the 
regions which reported to show linkage 
to atopy and asthma (Daniels et al., 1996; 
Malerba and Pignatti 2005). The gene 
encoding Clara cell secretory protein 16 
KDa (CC16; synonyms: Uteroglobin and 
CC10) has been mapped to this region 
(Hay et al., 1995). The protein sequence 
is evolutionary conserved among 
mammals, suggesting an important, if not 
critical, role in mammalian physiology 
(Hashimoto et al. 1996). It is the most 
common protein in the bronchoalveolar 
lavage fluid (BALF) of healthy non-
smokers (Bernard et al., 1992a). CC16 
levels are significantly lower in asthmatic 
patients (Shijubo et al., 1999; Van Vyve 
et al., 1995) and in smoker subjects 
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(Bernard et al., 1992b; Robin et al., 
2002). There is growing evidence from in 
vitro and in vivo studies suggesting that 
this protein plays an important protective 
role in the ling as an anti-inflammatory 
agent (Dierynck et al., 1995; Lesur et al., 
1995; Milele et al., 1987). Mice deficient 
in CC16 expression were found to exhibit 
a higher susceptibility to oxidant-induced 
lung injury and an excessive 
inflammatory response (Johnston et al., 
1997; Mango et al., 1998). 
 
Taken together, these evidences, suggest 
that CC16 plays a protective role in the 
lung, and it is possible that low activity 
variants of CC16 may be associated with 
inflammatory lung disorders such as 
asthma. 
 
The gene encoding CC16 is 5 kb in 
length, and is comprised of a 550-bp 5'-
untranslated region (5'UTR) and three 
exons (Hay et al. 1995). An 
adenine/guanine polymorphism at 
position 38 (A38G) downstream from the 
transcription start site was previously 
reported (Laing et al., 1998a). It is 
reported that the 38A allele has lower 
transcription levels than the 38G allele, 
suggesting a potential loss of anti-
inflammatory activity in the lung for 
individuals with the 38A allele (Laing et 
al., 2000). Several studies have examined 
the association between the A38G 
polymorphism of CC16 and 
susceptibility to asthma. The results of 
these studies, however, are not consistent 
(Bakhu et al., 1998; Baldini et al., 1998; 
Candelaria et al., 2005; Gao et al., 1998; 
Gui et al., 2003; Kalyoncu et al., 2003; 
Laing et al., 1998a; Laing et al., 1998b; 
Mansur et al., 2002; Mao et al., 1998; 
Saadat et al., 2004; Sanak et al., 1999; 
Sengler et al., 2003; Sharma and Ghosh 
2004). 
 
One of the main aims of genetic 
epidemiology is to understand the genetic 
contribution to complex diseases such as 
asthma. One of the most popular study 
designs in this area is a molecular 
association study in which a 
polymorphism is linked to the disease 
outcome in cases and controls. These 
studies are often limited by small sample 
sizes, so there is a role for meta-analysis 
in pooling these studies, particularly to 
detect the small effect sizes that may be 
associated with these polymorphisms. 
Most of the studies investigating the 
association between CC16 polymorphism 
and risk of asthma are based on small 
sample size (Candelaria et al., 2005; 
Kalyoncu et al., 2003; Laing et al., 
1998a; Mansur et al., 2002; Saadat et al., 
2004). In order to clarify the effect of 
CC16 genotype on the risk of developing 
asthma, we carried out a meta-analysis 
using published data from 1996 up to the 
August 2005, to obtain more precise 
estimates of risk. 
 
MATRIALS AND METHODS 
 
Identification of studies: 
Studies published between January 1998 
and August 2005 with information of 
CC16 genetic polymorphism and the risk 
of asthma were identified using 
electronic database, MEDLINE (National 
Library of Medicine, Washington, DC, 
USA). Search terms were "asthma" and 
"CC16" or "Clara cell protein". 
Additional articles were also checked 
using the references cited in these 
publications. 
 
Articles selected for analysis were 
studies with case-control design and their 
primary references, which had no 
obvious overlap of cases with other 
studies. Five studies were not including 
in the analysis because their cases 
showed overlap with other reports, 
presented as an abstracts in seminars or 
published in Chinese (Bakhu et al., 1998; 
Baldini et al., 1998; Gui et al., 2003; 
Laing et al., 1998b; Sanak et al., 1999;). 
Study of Mao et al. (1998) also excluded 
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from the analysis because the authors 
investigated the association between 
asthma and an intragenic variant of 
CC16. Studies of Gao et al. (1998) and 
also Sengler et al. (2003) that included 
different patients groups were considered 
as four studies in the analysis. The 
application of these criteria yielded 11 
case-control studies eligible for meta-
analysis (Candelaria et al., 2005; Gao et 
al., 1998; Kalyoncu et al., 2003; Laing et 
al., 1998a; Mansur et al., 2002; Saadat et 
al., 2004; Sengler et al., 2003; Sharma 
and Ghosh 2004). 
 
In all of the studies, the polymorphism 
was determined by PCR assays. The PCR 
was performed according to the method 
introduced by Laing et al (1998a). 
Amplification products were digested 
with Sau96I. Restriction digestion of 
amplified DNA samples showed three 
altered digested patterns identifying 
heterozygous and homozygous subjects 
for both 38A and 38G alleles. Genetic 
polymorphism was defined as AA 
(absence of restriction site on both 
alleles), GG (presence of restriction site 
on both alleles) or AG (heterozygous). It 
is suggested that the 38G allele is more 
likely to be the wild type allele (Laing et 
al., 1998a). 
 
Statistical analysis: 
For control group of each study allelic 
frequency was calculated. For control 
group of each study, the observed 
frequencies of the CC16 genotypes were 
assessed for Hardy-Weinberg 
equilibrium using the χ2 statistic. 
 
The odds ratio (OR) of asthma associated 
with the CC16 genetic polymorphism 
was re-calculated for each study, and 
their corresponding 95% confidence 
intervals (CI) were estimated. The results 
might not be exactly the same as those of 
some studies as different criteria were 
used in the statistical analysis. A low-risk 
genotype (GG) was used as the baseline 
for calculation ORs. For comparing the 
allelic distribution between patients and 
controls, the 38G allele was used as the 
baseline for calculation ORs. 
 
To take into account the possibility of 
heterogeneity across the studies, a 
statistical test for heterogeneity was 
performed based on the Q statistic, in 
which a P-value greater than 0.05 
suggested a lack of heterogeneity 
(DerSimonian and Laird 1986). We 
carried out meta-analysis using both a 
fixed-effects and a random-effects 
model. The fixed-effects method assumes 
no significant heterogeneity between the 
results of the individual studies being 
pooled, whereas, the random-effects 
method allows for such heterogeneity. 
The fixed-effects and random-effects 
methods were used by Mantel-Haenszel 
(Mantel and Haenszel 1959) and 
DerSimonian and Laird methods 
(DerSimonian and Laird 1986), 
respectively. In Tables we report the 
results of fixed-effects method and if 
there is heterogeneity between studies, 
we report the results of random-effect 
method. The analyses were also 
conducted on the subgroups of studies 
based on age and smoking status of the 
subjects. The p-value less than 0.05 
considered statistically significant. 
 
RESULTS 
 
Comparing CC16 allelic frequencies 
between patients and controls: 
We identified 11 eligible studies, 
including 2362 subjects (1100 patients, 
and 1262 healthy controls) in relation to 
the A38G polymorphism of CC16 and 
risk of asthma, which are summarized in 
Table 1. From these, 5, 5 and 1 studies 
were carried out in Asian and European 
countries and in Australia, respectively 
(Table 1). The numbers in the case-
control studies varied considerably 
(range 96 to 510 individuals). The 
frequency of the 38A allele varied in the 
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control participants, from 18.2 percent (in Iran) to 52.4 percent (in India). 
 
Table 1: Distributions of 38A and 38G alleles of CC16 in controls and asthmatic 
patients 
 Controls  Cases  Study Country Age 
Smoker G A Frequency 
of A (%) 
G A OR 95% CI 
Laing et al., 1998a Australia Child None 68 24 26.1 76 58 2.16 1.17-4.02 
Gao et al., 1998 England Adult Some 186 114 38.0 169 81 0.78 0.54-1.13 
Gao et al., 1998 Japan Adult Some 122 78 39.0 121 79 1.02 0.67-1.56 
Gao et al., 1998 Japan Adult Some 122 78 39.0 122 78 1.00 0.66-1.53 
Mansur et al.,2002  England Adult Some 52 30 36.6 113 61 0.94 0.52-1.68 
Sengler et al., 2003 Germany Child None 163 73 30.9 113 55 1.09 0.70-1.70 
Sengler et al., 2003 Germany Child None 163 73 30.9 144 64 0.99 0.65-1.52 
Kalyoncu et al., 2003 Turkey Adult ? * 81 29 26.4 55 27 1.37 0.70-2.69 
Saadat et al., 2004 Iran Adult None 139 31 18.2 121 49 1.82 1.06-3.13 
Sharma & Ghosh 2004 India Adult None 239 263 52.4 256 262 0.93 0.72-1.20 
Candelovia et al., 2005 Denmark Adult Some 547 285 34.3 51 45 1.69 1.08-2.65 
* The smoking status of subjects was not mention in the article. 
** The 38A and 38G are the low and high risk alleles, respectively. 
 
Table 2 shows the association between 
frequency of the 38A allele and 
susceptibility to asthma. Test for 
heterogeneity between studies showed 
heterogeneity between the studies (Q 
statistic=19.648, df=10, P<0.05). 
Therefore, the random-effects model was 
used for calculation of OR and its 95% 
CI (Table 2). The overall OR of the 
asthma risk associated with the 38A 
allele of the CC16 gene was 1.09 (95% 
CI: 0.96-1.23) which is not statistically 
significant. 
 
Table 2: Summary of meta-analysis of case-control studies of CC16 polymorphism 
and the risk of asthma, distribution of 38A allele between cases and controls 
 Q statistic df OR 95% CI 
All of studies 19.648* 10 1.09 0.96-1.23 
Adulthood 13.806 6 1.05 0.91-1.21 
Childhood 5.056 2 1.21 0.93-1.58 
Non-smokers 10.97* 4 1.12 0.94-1.32 
Smokers 7.72 4 1.03 0.85-1.24 
* There is heterogeneity between studies P<0.05. 
Table 2 also summaries the results of the 
stratified meta-analysis. Subgroup 
analysis, regarding age and smoking 
status of the subjects were carried out. 
Studies were stratified according to the 
age of subjects (adulthood and 
childhood). Three studies investigated 
the association between the frequency of 
CC16 alleles and risk of asthma in 
children. The total sample size was 255 
with asthma and 164 controls. Eight 
studies assessed the association between 
the frequencies of CC16 alleles and 
asthma risk in adults. The sample size 
was 845 for asthma and 1098 for 
controls. No heterogeneity was detected 
between the studies (For adulthood: Q 
statistic= 13.806, df=6, P>0.05; For 
childhood: Q statistic=5.056, df=2, 
P>0.05). Statistical analysis showed there 
is no significant association between the 
frequency of the 38A allele and asthma 
risk in the both groups (For adulthood 
OR=1.05, 95% CI: 0.91-1.21; For 
childhood OR=1.21, 95% CI: 0.93-1.58). 
 
In order to investigate the possible 
interaction between cigarette smoking 
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and the genotypes of CC16, the studies 
were stratified according to the smoking 
status of the subjects. Study of Kalyoncu 
et al. (2003) did not mention the smoking 
status of their subjects; therefore, we 
excluded this study for the analysis. Five 
studies determined the association 
between the frequencies of CC16 alleles 
and asthma in non-smokers. Total sample 
size was 599 with asthma and 500 
control subjects. There was significant 
heterogeneity between the studies (Q 
statistics=10.97, df=4, P<0.05). 
Therefore the OR was calculated using 
random-effects method. Five studies 
investigated the association between the 
frequency of CC16 alleles and asthma 
risk in smoker subjects. Total sample size 
was 460 subjects with asthma and 707 
healthy persons as control group. There 
was no heterogeneity between the studies 
(Q statistics=7.72, df=4, P>0.05). 
Association between the frequency of 
CC16 alleles and asthma was not 
statistically significant (For smokers: 
OR=1.03, 95% CI: 0.85-1.24; For non-
smokers: OR= 1.12, 95% CI: 0.94-1.32). 
 
Comparing the CC16 genotypic 
frequencies between patients and 
controls: 
Table 3 summaries CC16 genotypic 
frequencies in patients and controls of the 
studies included in the meta-analysis. 
Here the study of Laing et al. (1998a) 
was excluded, because the raw data of 
the genotypes frequencies was not 
available. The CC16 genotype 
frequencies in all of the control groups 
were in Hardy-Weinberg equilibrium 
(P>0.05, data not shown). Here we 
analyzed the following comparisons: 
 
a) AG genotype versus GG 
genotype 
 
b) AA genotype versus GG 
genotype 
 
c) AA+AG genotypes versus GG 
genotype 
 
In pooled and in all of the subgroup 
analyses, there was no identifiable 
evidence of heterogeneity in the analyses 
of CC16 and asthma risk (Table 4). The 
overall ORs of the asthma risk were not 
associated with the CC16 genotypes (For 
AG vs GG: OR=1.09, 95% CI: 0.90-
1.32; For AA vs GG: OR=1.05, 95% CI: 
0.79-1.39; For AG+AA vs GG: 
OR=1.09, 95% CI: 0.91-1.30). It should 
be noted that when we used the stratified 
data, based on age and smoking status of 
subjects, same results were obtained 
(Table 4). 
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Table 3: Distributions of CC16 genotypes in controls and asthmatic patients 
 Controls    Cases    AG vs GG   AA vs GG   AA+AG vs GG Study  χ2 for HW* 
GG GA AA  GG GA AA  OR 95% CI  OR 95% CI  OR 95% CI 
Gao et al., 1998  0.88 55 76 19  54 61 10  0.82 0.48-1.40  0.54 0.21-1.35  0.76 0.45-1.27 
Gao et al., 1998  0.25 36 50 14  36 49 15  0.98 0.51-1.88  1.07 0.41-2.77  1.00 0.54-1.86 
Gao et al., 1998  - 36 50 14  41 40 19  0.70 0.36-1.35  1.19 0.48-2.94  0.81 0.44-1.49 
Mansur et al.,2002   0.11 17 18 6  37 39 11  1.00 0.41-2.39  0.84 0.23-3.09  0.96 0.42-2.17 
Sengler et al., 2003  0.09 57 49 12  35 43 6  1.43 0.76-2.68  0.81 0.25-2.62  1.31 0.72-2.39 
Sengler et al., 2003  - 57 49 12  48 48 8  1.16 0.64-2.10  0.79 0.27-2.30  1.09 0.62-1.91 
Kalyoncu et al., 2003  0.02 30 21 4  18 19 4  1.51 0.59-3.87  1.67 0.30-9.36  1.53 0.63-3.76 
Saadat et al., 2004  0.74 58 23 4  45 31 9  1.74 0.85-3.57  2.90 0.75-12.1  1.91 0.98-3.75 
Sharma and Ghosh 2004  1.67 62 115 74  68 119 72  0.94 0.60-1.48  0.89 0.54-1.46  0.92 0.61-1.40 
Candelovia et al., 2005  2.19 173 201 42  13 25 10  1.66 0.78-3.54  3.17 1.19-8.39  1.92 0.95-3.94 
* Testing for Hardy-Weinberg equilibrium, df=1, P>0.05 
** The GG is the low risk genotype. 
 
 
Table 4: Summary of meta-analysis of case-control studies of CC16 polymorphism and the risk of asthma, distribution 
of the CC16 genotypes between cases and controls 
   AG vs GG   AA vs GG   AA+AG vs GG  
Study df Q statistic OR 95% CI  Q statistic OR 95% CI  Q statistic OR 95% CI 
All of studies 9 8.51 1.09 0.90-1.32  12.49 1.05 0.79-1.39  10.96 1.09 0.91-1.30 
Adulthood 7 7.41 1.04 0.83-1.29  11.83 1.09 0.81-1.49  10.47 1.06 0.87-1.30 
Childhood 1 0.25 1.28 0.84-1.96  0.001 0.80 0.37-1.74  0.21 1.19 0.79-1.78 
Non-smokers 3 2.75 1.19 0.91-1.58  3.40 0.97 0.66-1.44  3.96 1.16 0.89-1.51 
Smokers 4 3.71 0.94 0.69-1.27  8.36 1.10 0.72-1.70  5.37 0.98 0.75-1.29 
Note: There is no heterogeneity between studies P<0.05. 
DISCUSSION 
 
The overall goal of meta-analysis is to 
combine the results of previous studies to 
arrive at summary conclusions about a 
body of research. It is most useful in 
summarizing prior research when 
individual studies are small and they are 
individually too small to yield a valid 
conclusion. In the present study, 11 case-
control studies were found eligible for 
meta-analysis (Candelaria et al., 2005; 
Gao et al., 1998; Kalyoncu et al., 2003; 
Laing et al., 1998a; Mansur et al., 2002; 
Saadat et al., 2004; Sengler et al., 2003; 
Sharma and Ghosh 2004). There was no 
evidence of heterogeneity between 
studies in the present meta-analysis 
(Tables 2 and 4). The present results 
show no association between the A38G 
polymorphism of the CC16 gene and risk 
of asthma, thus providing evidence 
against a major role played by this 
polymorphism in the predisposition to 
asthma. This finding is not consistent 
with the location of CC16 on human 
chromosome (Hay et al., 1995), genome-
wide searches (Daniels et al., 1996; 
Malerba and Pignatti, 2005), 
physiological functions of CC16 
(Bernard et al., 1992a; Dierynck et al., 
1995; Johnston et al., 1997; Lesur et al., 
1995; Mango et al., 1998; Milele et al., 
1987; Shijubo et al., 1999; Van Vyve et 
al., 1995;), and alterations of CC16 levels 
in the serum of smoker subjects (Bernard 
et al., 1992b; Robin et al., 2002) and 
asthmatic patients (Shijubo et al., 1999; 
Van Vyve et al., 1995). This may be due 
to following reasons: 
 
First: The human CC16 gene maps to an 
important genetic region which has been 
linked by various studies to asthma and 
its related phenotypes (Cookson et al., 
1989; Daniels et al., 1996). In addition to 
the CC16 gene, several other known 
potential candidate gene(s) is the target 
remains a matter of debate. 
Polymorphisms in other genes located on 
human 11q (FcεRI-β and GSTP1) have 
been associated with total serum IgE, 
atopy and BHR (Fryer et al., 2000; Hill et 
al., 1995; Shirkawa et al., 1994). 
Additionally the region is likely to 
harbour other genes yet to be identified. 
Second: There is few studies showed 
significant association between A38G 
polymorphism and asthma risk 
(Candelovia et al., 2005; Laing et al., 
1998a; Saadat et al., 2004). However, 
several studies (Gao et al., 1998; 
Kalyoncu et al., 2003; Mansur et al., 
2002; Sengler et al., 2003; Sharma and 
Ghosh 2004) and also the results of the 
present study failed to replicate the 
association between the A38G 
polymorphism of CC16 and asthma. The 
A38G polymorphism of CC16 and the 
intragenic microsatellite repeat 
polymorphism intron 1 at the haplotype 
level was investigated in a case-control 
study in India (Sharma and Ghosh 2004). 
The authors also attempted to evaluate 
the association between these markers 
individually and at the haplotype level to 
asthma status. They found the significant 
association between the above-mentioned 
markers and asthma risk (Sharma and 
Ghosh 2004). It is probable that this is 
not an effect of the single nucleotide 
polymorphism of CC16, but instead, 
reflects a common haplotype that 
includes this allele. At least in part, the 
phenomenon of linkage disequilibrium 
between the 38A allele and other loci 
involved in developing asthma might be 
into account. 
 
Third: Asthma is a complex disorder 
caused by the additive effects of many 
genes and environmental factors and 
their interactions which each having only 
a small effect on developing the 
phenotype. It is reported that the GST 
genes and other genes involved in the 
oxidation stress have been described to 
be involved in asthma and atopy (Fryer et 
al., 2000; Tamer et al., 2004). Gene 
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polymorphisms of the several members 
of GST superfamily (such as GSTP1, 
GSTT1, GSTM1) have been associated 
with asthma and atopy (Fryer et al., 
2000; Saadat et al., 2004; Tamer et al., 
2004). We have recently reported a 
strong association between the 
combination genotypes of genetic 
polymorphisms of CC16, GSTM1, and 
GSTT1 and asthma in a case-control 
study (Saadat et al., 2004). We found that 
the concurrent lack of the GSTM1 and 
GSTT1 genes increased asthma risk 
about 10.23 (P<0.001). On the other hand 
we found a weak association between 
38A allele and risk of asthma. However, 
when combination of CC16, GSTM1, 
and GSTT1 genotypes was analyzed, we 
found that individuals AA or AG 
genotypes when lack of both of the active 
genes of GSTM1 and GSTT1 posed more 
than a 22-fold odds of asthma. The 
additive effect of genetic polymorphisms 
of GSTM1 and GSTT1 was reported for 
developing several types of cancers, such 
as gastric and colorectal cancers (Saadat 
and Saadat 2001) and asthma 
(Invaschenko et al., 2002). It is probable 
that the CC16 polymorphism has very 
small effect on the susceptibility of 
asthma, but its combination with other 
genes, results on increased the 
association between genetic 
polymorphisms and asthma. Therefore, it 
would be interesting to investigate the 
additive effects of several genes (either 
located on chromosome 11q or located 
on the other chromosomes) involved in 
the developing asthma. 
 
Forth: Suppose that we wished to test 
that presence of 38A allele has the effect 
of increasing the risk of asthma about 
1.10 (OR). With 80% power, for 
detecting a difference at the 0.05 level, 
we would require about 15200 subjects 
(7600 patients and 7600 controls). The 
number of subjects, in the present meta-
analysis is about 2600, which is much 
lower than the required samples. This 
warrants further investigation in larger 
studies. 
 
It might be concluded that the 
relationship between the CC16 genotypic 
variation and susceptibility to asthma is 
still an open question. The above 
mentioned points suggest that in the 
future research in this field should take 
great care in the interaction between 
healthy risk factor (life-style conditions, 
such as smoking behavior, alcohol and 
air pollution) and combination genotypes 
of CC16 and other genes (such as 
GSTM1, GSTT1, GSTP1 genes). Also 
additive effect of involved genes should 
be investigated. 
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